Fundraising FoxHealthspan Capital — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety.
BiotechDeep TechHealthtechAllston, US
Dario Doller(Co-founder)inKevin Hodgetts(Founding Lab / Co-founder)inAndrew Thomson(Executive Officer, Director, Promoter)in
Co-investorsPillar VCPalo Santo VC
Oisín Biotechnologies develops non-viral genetic therapies built on its Fusogenix Proteo-Lipid Vehicle (PLV) delivery platform, which delivers DNA and RNA payloads to tissues throughout the body and allows repeat dosing.
BiotechHealthtechLongevitySeattle, US
Matthew Scholz(Executive Officer, Director)inEric Garcia(Executive Officer)inStephen Hilbert(Executive Officer)John Lewis(Executive Officer)inGary Hudson(Executive Officer, Director)in
BoardDavid Gobel(Director)
Co-investorsIKJ Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.